Active
Comirnaty
The mRNA COVID-19 vaccine (BNT162b2 / tozinameran) co-developed and commercialized with Pfizer - the first mRNA vaccine authorized for human use and the product that validated the platform at global scale.
BioNTechBNT327 (pumitamig)
In Development
BioNTech's flagship oncology asset: a next-generation bispecific antibody targeting both PD-L1 and VEGF-A, gained via the Biotheus acquisition and positioned as a potential immuno-oncology backbone across many solid tumors. Co-developed with Bristol Myers Squibb.
Latest update Sep 15, 2026
01
Current status
Seven pivotal trials in the ROSETTA program under way (five initiated in H1 2026 alone) across small-cell and non-small-cell lung cancer, triple-negative breast, gastric and colorectal cancers. More than 1,000 patients treated to date; ASCO 2026 data marked the third global dataset consistently showing efficacy across PD-L1 expression levels, with registrational first-line lung-cancer readouts still expected in 2026. At WCLC 2026 (September 12), first pumitamig plus elfetabart drozuntecan combo data showed a 70.4% ORR and 93.0% DCR in 71 evaluable SCLC patients.
02
Specifications2
03
Upcoming milestones2
Announced next steps from BioNTech that mention BNT327 (pumitamig).
2026-2027
BNT327 first-line lung-cancer Phase 3 readouts
Report registrational Phase 3 data for BNT327 (pumitamig) in first-line lung cancer - the key catalyst for its central immuno-oncology bet with Bristol Myers Squibb. The pivotal ROSETTA program (7 trials, 5 initiated in H1 2026) spans ROSETTA Lung-01 (1L extensive-stage small-cell lung cancer), ROSETTA Lung-02 (1L non-small-cell lung cancer), ROSETTA Lung-201 (unresectable stage III NSCLC vs durvalumab) and ROSETTA Lung-202 (1L PD-L1>=50% NSCLC vs pembrolizumab). As of the August 2026 Q2 update, ASCO 2026 data marked a third consistent global dataset showing efficacy across PD-L1 levels, but the registrational Phase 3 portions remain recruiting with no pivotal readout yet. BioNTech now runs 16 lung-cancer trials companywide (5 pivotal Phase 3 plus 2 novel-novel combination studies). WCLC 2026 (Seoul, September 12-15) delivered first pumitamig plus elfetabart drozuntecan combo data (70.4% ORR in SCLC) and the first median OS for gotistobart in PRESERVE-003 stage 1.
2030
Become a multi-product oncology company by 2030
Scale BNT327 across its seven-plus pivotal indications and broaden the now-14-trial pivotal pipeline (spanning trastuzumab pamirtecan, elfetabart drozuntecan and gotistobart) while deploying the ~€16.6B cash reserve and cutting COVID-era manufacturing costs, targeting multiple approved cancer products by the end of the decade. Markets rewarded the pivot on August 19, 2026, when the stock jumped ~23% as investors refocused on the oncology pipeline. WCLC 2026 combo and gotistobart data are the latest visibility points; no oncology product is approved yet.
04
More from BioNTech6
- In Development
Autogene cevumeran (BNT122)
An individualized neoantigen-specific mRNA cancer vaccine, custom-manufactured for each patient's tumor mutations and co-developed with Genentech (Roche) to train the immune system against residual disease after surgery.
- In Development
Trastuzumab pamirtecan (BNT323/DB-1303)
A HER2-targeted antibody-drug conjugate (third-generation topoisomerase-1 inhibitor payload) co-developed with China's DualityBio - BioNTech's lead candidate for its first-ever cancer-drug regulatory submission, being tested in HER2-expressing endometrial cancer and HER2-positive breast cancer.
- In Development
Elfetabart drozuntecan (BNT324/DB-1311)
A next-generation, topoisomerase-1-inhibitor-based antibody-drug conjugate targeting the immune-checkpoint protein B7-H3, co-developed with China's DualityBio - BioNTech's third late-stage oncology asset alongside BNT327 and trastuzumab pamirtecan, with clinical experience across more than ten tumor types.
- In Development
Gotistobart (BNT316/ONC-392)
A next-generation, pH-sensitive anti-CTLA-4 antibody designed to deplete regulatory T cells within tumors while sparing normal tissue, co-developed with OncoC4 since a March 2023 strategic collaboration ($200M upfront to OncoC4, costs and profits split on PD-(L)1 combination studies, BioNTech holding exclusive worldwide commercialization rights). It is BioNTech's fourth late-stage oncology asset alongside BNT327, trastuzumab pamirtecan, and elfetabart drozuntecan.
- In Development
BNT113 (tenumomeran/raplemomeran)
Investigational mRNA cancer immunotherapy encoding the HPV16 E6 and E7 proteins, also called tenu-ra. It is designed to induce HPV16-specific immune responses alongside checkpoint-inhibitor treatment. The lead study is AHEAD-MERIT (NCT04534205), a Phase 2/3 trial of BNT113 plus pembrolizumab versus pembrolizumab alone in first-line unresectable recurrent or metastatic HPV16-positive, PD-L1-expressing head and neck cancer.
05
More in Biotech
In DevelopmentAurora Powerhouse
Oklo
Oklo's fast-fission powerhouse product line is designed for build-own-operate deployment, targeting customers that want firm clean power in a smaller footprint than traditional large reactors.
In DevelopmentFuel Recycling
Oklo
Oklo is developing an advanced fuel center to recycle used nuclear fuel and fabricate metal fuel for Aurora and other fast-reactor applications.
In DevelopmentNatrium
TerraPower
Sodium-cooled fast reactor with integrated molten salt energy storage, enabling flexible output from 345 MWe to 500 MWe peak.
In DevelopmentMolten Salt Energy Storage
TerraPower
Integrated thermal energy storage system using molten salt to decouple reactor output from grid delivery, enabling peak power output.